ABBV Stocktwits, News and Mentions. Forecasting AbbVie Inc. Sentiments







6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

February 15, 2024 Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…

ABBV Stock News and Mentions of AbbVie Inc. Stocktwits

Updated: March 29, 2024 (09:56)

Sector: Healthcare

Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.

We meticulously analyze the sentiment trend in each article for the last 60 days where AbbVie Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of AbbVie Inc. (ABBV).

You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the AbbVie stocks.


Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles

News and Mentions of AbbVie Inc. (ABBV)

March 28, 2024 (15:17) / "Zacks Commentary" (by Zacks Investment Research)

C3.ai ( AI ) , Paradyme Extend Partnership to Deliver AI Solutions

C3.ai (AI) expands partnership agreement with Paradyme that aims at accelerating the delivery of AI solutions tailored for the U.S. Intelligence Community.
In Article Trend: Somewhat-Bullish
March 28, 2024 (13:50) / "Zacks Commentary" (by Kinjel Shah)

Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs

While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)

Should WisdomTree U.S. High Dividend ETF ( DHS ) Be on Your Investing Radar?

Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:00) / "GlobeNewswire" (by Zymeworks Inc.)

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

VANCOUVER, British Columbia, March 28, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:00) / "Benzinga" (by Globe Newswire)

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors - Syndax Pharmaceuticals ( NASDAQ:SNDX ) , Zymeworks ( NASDAQ:ZYME )

VANCOUVER, British Columbia, March 28, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ZYME, a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (21:58) / "Forbes" (by Katie Jennings)

InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV

InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. s a postdoctoral researcher at the Broad Institute of MIT and Harvard, Nicole Gaudelli was the co-inventor of a breakthrough in gene editing: the ability to target a single misspelling in DNA code.
In Article Trend: Somewhat-Bullish
March 27, 2024 (18:00) / "Benzinga" (by Benzinga Insights)

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie ( NYSE:ABBV )

AbbVie ABBV has outperformed the market over the past 10 years by 2.45% on an annualized basis producing an average annual return of 13.15%. Currently, AbbVie has a market capitalization of $317.49 billion.
In Article Trend: Somewhat-Bullish
March 27, 2024 (17:00) / "GlobeNewswire" (by OSE Immunotherapeutics)
March 27, 2024 (15:07) / "Benzinga" (by Globe Newswire)

Kuehn Law Encourages LABP, WRK, KAMN and TGAN Investors to Contact Law Firm - Landos Biopharma ( NASDAQ:LABP ) , Kaman ( NYSE:KAMN )

NEW YORK, March 27, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
In Article Trend: Bullish
March 26, 2024 (18:00) / "PR Newswire" (by Research and Markets)

Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie, AstraZeneca, Merck & Co., Novartis, Pfizer and more

Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (16:00) / "Benzinga" (by Benzinga Insights)

Assessing AbbVie's Performance Against Competitors In Biotechnology Industry - AbbVie ( NYSE:ABBV )

In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating AbbVie ABBV in relation to its major competitors in the ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:03) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) to Buy Landos to Strengthen Autoimmune Portfolio

AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
In Article Trend: Somewhat-Bullish
March 25, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) Advances While Market Declines: Some Information for Investors

AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.
In Article Trend: Somewhat-Bullish
March 25, 2024 (19:00) / "Benzinga" (by Avi Kapoor)

Nasdaq Turns Higher; Akanda Shares Plunge - Akanda ( NASDAQ:AKAN ) , AbbVie ( NYSE:ABBV )

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also fell, dropping, 0.12% to 5,227.95. In trading on Monday, industrials shares fell by 0.5%.
In Article Trend: Neutral
March 25, 2024 (15:54) / "Benzinga" (by Avi Kapoor)

Crude Oil Moves Higher; US New Home Sales Fall In February - Akanda ( NASDAQ:AKAN ) , AbbVie ( NYSE:ABBV )

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S&P 500 also fell, dropping, 0.16% to 5,226.01. In trading on Monday, communication services ...
In Article Trend: Neutral
March 25, 2024 (15:45) / "Zacks Commentary" (by Zacks Equity Research)

Why AbbVie ( ABBV ) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
In Article Trend: Bullish
March 25, 2024 (15:27) / "Benzinga" (by Vandana Singh)

Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? - Landos Biopharma ( NASDAQ:LABP )

Monday, AbbVie Inc ABBV agreed to acquire Landos Biopharma Inc LABP for $20.42 per share, or approximately $137.5 million in the aggregate, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million.
In Article Trend: Somewhat-Bullish
March 25, 2024 (15:09) / "Benzinga" (by Globe Newswire)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. ( NYSE - AGTI ) , Landos Biopharma, Inc. ( Nasdaq - LABP ) , Fusion Pharmaceuticals Inc. ( Nasdaq - FUSN ) , Kinnate Biopharma Inc. ( Nasdaq - KNTE )

BALA CYNWYD, Pa., March 25, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:42) / "Benzinga" (by Avi Kapoor)

US Stocks Down; Chicago Fed National Activity Index Rises In February - Akanda ( NASDAQ:AKAN ) , AbbVie ( NYSE:ABBV )

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell 0.42% to 16,359.31. The S&P 500 also fell, dropping, 0.23% to 5,222.33.
In Article Trend: Neutral
March 25, 2024 (13:10) / "Benzinga" (by Globe Newswire)

Professional Diversity Network ( PDN ) Hosts Successful Virtual Career Fair for Women's History Month - Professional Diversity ( NASDAQ:IPDN )

CHICAGO, March 25, 2024 ( GLOBE NEWSWIRE ) -- Professional Diversity Network, Inc.
In Article Trend: Bullish
March 25, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:10) / "GlobeNewswire" (by Professional Diversity Network)

Professional Diversity Network ( PDN ) Hosts Successful Virtual Career Fair for Women's History Month

CHICAGO, March 25, 2024 ( GLOBE NEWSWIRE ) -- Professional Diversity Network, Inc. ( NASDAQ: IPDN ) ( "PDN" or the "Company" ) , a developer and operator of online and in-person networks that provide access to networking, training, educational, and employment opportunities for diverse ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)

Investors Heavily Search AbbVie Inc. ( ABBV ) : Here is What You Need to Know

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:31) / "PR Newswire" (by AbbVie)

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. ( NYSE: ABBV ) ( "AbbVie" ) and Landos Biopharma, Inc. ( NASDAQ: LABP ) ( "Landos" ) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:30) / "GlobeNewswire" (by Landos Biopharma)

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

- Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis ( UC ) - Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis ( UC ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:30) / "Benzinga" (by Globe Newswire)

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases - Landos Biopharma ( NASDAQ:LABP ) , AbbVie ( NYSE:ABBV )

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 ( GLOBE NEWSWIRE ) -- AbbVie Inc. ABBV ( "AbbVie" ) and Landos Biopharma, Inc.
In Article Trend: Somewhat-Bullish
March 25, 2024 (11:00) / "Forbes" (by Dmitry Reykhart)

Council Post: What's Driving Big Pharma's Recent Market Performance?

What's Driving Big Pharma's Recent Market Performance? Forbes ...
In Article Trend: Neutral
March 25, 2024 (11:00) / "Benzinga" (by Globe Newswire)

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors - Mirum Pharmaceuticals ( NASDAQ:MIRM ) , Century Therapeutics ( NASDAQ:IPSC )

SAN MATEO, Calif., March 25, 2024 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc. ( ( Sagimet, NASDAQ:SGMT ) , a clinical-stage biopharmaceutical company developing novel fatty acid synthase ( FASN ) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (21:17) / "Forbes" (by James Farrell)

AbbVie's New 'Biological Missile' Ovarian Cancer Treatment Gets Full FDA Approval

The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen's cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments considered "biological missiles" because of their ability to precisely home in on cancer cells.
In Article Trend: Somewhat-Bearish
March 22, 2024 (16:18) / "PR Newswire"

Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire

Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (09:38) / "Money Control"

M&A is back. Expect losers to outnumber winners

Many publicly traded companies are now sitting on sizeable cash reserves and borrowing costs appear to be stable. Buyout funds, too, are awash with cash and itching to deploy it. The worry must be that financial firepower, frustration and a fear of missing out make for ill-disciplined ...
In Article Trend: Neutral
March 21, 2024 (15:01) / "Benzinga" (by Benzinga Insights)

AbbVie Recent Insider Activity - AbbVie ( NYSE:ABBV )

Making a noteworthy insider sell on March 20, Jeffrey R. Stewart, EVP at AbbVie ABBV, is reported in the latest SEC filing. What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday outlined that Stewart executed a sale of 58,949 shares of AbbVie with a total ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (20:15) / "GlobeNewswire" (by Alvotech)

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a summary of recent pipeline and corporate highlights.
In Article Trend: Neutral
March 20, 2024 (20:15) / "GlobeNewswire" (by Alvotech)

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

REYKJAVIK, Iceland, March 20, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a ...
In Article Trend: Neutral
March 20, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)

Is First Trust Value Line Dividend ETF ( FVD ) a Strong ETF Right Now?

Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (09:48) / "Zacks Commentary" (by Zacks Investment Research)

The Zacks Analyst Blog Highlights Mastercard, AbbVie, Salesforce, Thermo Fisher Scientific and Mondelez

Mastercard, AbbVie, Salesforce, Thermo Fisher Scientific and Mondelez are included in this Analyst Blog.
In Article Trend: Somewhat-Bullish
March 19, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, AbbVie (ABBV) closed at $179.66, indicating a +0.66% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
March 19, 2024 (18:20) / "Benzinga" (by Globe Newswire)

US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies

EXTON, PA, March 19, 2024 ( GLOBE NEWSWIRE ) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising pathway for delivering genetic material with precision and safety.
In Article Trend: Somewhat-Bullish
March 19, 2024 (16:45) / "Zacks Commentary" (by Sheraz Mian)

Top Analyst Reports for Mastercard, AbbVie & Salesforce

Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AbbVie Inc. (ABBV) and Salesforce, Inc. (CRM).
In Article Trend: Somewhat-Bullish
March 19, 2024 (12:45) / "GlobeNewswire" (by Autonomix Medical)

Autonomix Appoints Jennifer Cook as Chief Business Officer

Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (06:00) / "Business Insider" (by markets.businessinsider.com)

EQS-News: Newron presents 2023 financial results and provides 2024 outlook

Newron presents 2023 financial results and provides 2024 outlook
In Article Trend: Somewhat-Bullish
March 18, 2024 (15:30) / "Benzinga" (by Benzinga Insights)

Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today - AbbVie ( NYSE:ABBV )

AbbVie ABBV has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 13.21%. Currently, AbbVie has a market capitalization of $316.78 billion.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
March 17, 2024 (17:08) / "Benzinga" (by Globe Newswire)

Lutikizumab Clinical Trials Approved Bispecific Antibodies Market Insight

Delhi, March 17, 2024 ( GLOBE NEWSWIRE ) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 Billion Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies
In Article Trend: Neutral
March 17, 2024 (14:05) / "Motley Fool" (by Selena Maranjian)

These 7 Index ETFs Are a Retiree's Best Friend

One of these ETFs has averaged annual gains of nearly 15% over the past decade.
In Article Trend: Somewhat-Bullish
March 17, 2024 (12:15) / "Motley Fool" (by Prosper Junior Bakiny)

2 Top Dividend Stocks to Buy Hand Over Fist

Every company faces headwinds eventually. The top ones know how to bounce back.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)

Monoclonal Antibody ( mABs ) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™

CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (21:00) / "PR Newswire" (by I-Mab)

I-Mab Reports Full Year 2023 Financial Results and Business Update

ROCKVILLE, Md., March 14, 2024 /PRNewswire/ -- I-Mab ( the "Company" ) ( NASDAQ: IMAB ) , a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced financial ...
In Article Trend: Neutral
March 14, 2024 (17:16) / "Benzinga" (by Benzinga Insights)

Decoding AbbVie's Options Activity: What's the Big Picture? - AbbVie ( NYSE:ABBV )

Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 69% ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)

Why AbbVie ( ABBV ) Dipped More Than Broader Market Today

In the latest trading session, AbbVie (ABBV) closed at $179.86, marking a -0.59% move from the previous day.
In Article Trend: Somewhat-Bullish
March 13, 2024 (10:34) / "Benzinga" (by Globe Newswire)

Hormonal Contraceptive Market is Set to Achieve Staggering USD 33.8 billion Valuation by 2031 with 5.0% CAGR | Analysis by Transparency Market Research, Inc.

Wilmington, Delaware, United States, March 13, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The forecasted market valuation of the global hormonal contraceptive market by 2031 is about US$ 33.8 billion. This market advancement is moderate at a CAGR of 5.0%.
In Article Trend: Neutral
March 13, 2024 (05:30) / "Barrons" (by Lewis Braham)

This Top Fund Likes Microsoft, Visa, AT&T, and Other Dividend Growth Plays

Stocks that pay dividends can soften the impact when the market is falling. Yet they often prove a drag on the way up, compared with faster-growing companies. Achieving a balance between defense and offense can be tricky for investors.
In Article Trend: Somewhat-Bullish
March 12, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)

Here is What to Know Beyond Why AbbVie Inc. ( ABBV ) is a Trending Stock

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
March 12, 2024 (09:39) / "Zacks Commentary" (by Zacks Equity Research)

J&J ( JNJ ) Seeks Expanded Use of Tremfya for Ulcerative Colitis

Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.
In Article Trend: Somewhat-Bullish
March 11, 2024 (15:30) / "Benzinga" (by Globe Newswire)

Iron Deficiency Injectable Market Size Is Expected To Reach A Value Of $20.6 Billion By 2028 As Per The Business Research Company's Iron Deficiency Injectable Global Market Report 2024

LONDON, March 11, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Iron Deficiency Injectable Global Market Report 2024, the iron deficiency injectable market is experiencing rapid growth, poised to expand from $12.75 billion in 2023 to $14.06 billion in 2024, representing a ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (14:41) / "Investors Business Daily" (by Investor's Business Daily)

MoonLake Jumps As It Looks To Take On AbbVie Blockbuster, Humira

Biotech Stock MoonLake Rises After Arthritis Drug Tops AbbVie's Humira Investor's Business Daily ...
In Article Trend: Neutral
March 11, 2024 (13:56) / "Benzinga" (by Vandana Singh)

Why Is MoonLake Immunotherapeutics Stock Trading Higher Today? - MoonLake ( NASDAQ:MLTX )

On Sunday, MoonLake Immunotherapeutics MLTX announced that continued treatment with Nanobody sonelokimab led to significant improvements across all key outcomes at 24-week data from the ARGO trial in psoriatic arthritis ( PsA ) .
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:28) / "Motley Fool" (by Justin Pope)

3 Pharmaceutical Stocks to Buy Hand Over Fist in March

There are some great companies at attractive prices in the lucrative pharmaceutical space.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
March 9, 2024 (20:49) / "Business Insider" (by Muslim Farooque)

3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024

Last year emerged as a time of unexpected resilience and expansion for the stock market driven by the strength of unstoppable mega-cap stocks. Notably, the S&P 500 wrapped up last year with a solid 24% gain, turning heads in the process.
In Article Trend: Somewhat-Bullish
March 9, 2024 (15:05) / "Benzinga" (by Globe Newswire)

Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology ( AAD ) Annual Meeting

INCHEON, Korea, March 09, 2024 ( GLOBE NEWSWIRE ) -- Samsung Bioepis Co., Ltd. presented two new study results for its immunology portfolio - SB5, a biosimilar to Humira1 ( adalimumab ) , and SB17, a proposed biosimilar to Stelara2 ( ustekinumab ) - at the 2024 American Academy of Dermatology ( ...
In Article Trend: Neutral
March 9, 2024 (07:59) / "Motley Fool" (by Rachel Warren)

Have $2,500? 2 Superior Growth Stocks to Buy in 2024

These businesses can pack a punch in your portfolio over the long run.
In Article Trend: Neutral
March 8, 2024 (16:45) / "Zacks Commentary" (by Zacks Equity Research)

Why AbbVie ( ABBV ) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
In Article Trend: Bullish
March 8, 2024 (15:59) / "Money Morning" (by Chris Johnson)

This is Just the Beginning of Mind Medicine

My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, "Why The Psychedelic Boom Is All but Inevitable" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:02) / "Benzinga" (by Vandana Singh)

FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer - BeiGene ( NASDAQ:BGNE )

Thursday, the FDA granted accelerated approval to BeiGene Ltd's BGNE Brukinsa ( zanubrutinib ) for adult patients with relapsed or refractory ( R/R ) follicular lymphoma ( FL ) , in combination with Roche Holdings AG's RHHBY Gazyva ( obinutuzumab ) , after two or more lines of systemic therapy.
In Article Trend: Somewhat-Bullish
March 8, 2024 (05:30) / "Motley Fool" (by Motley Fool Transcribing)

MacroGenics ( MGNX ) Q4 2023 Earnings Call Transcript

MGNX earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
March 7, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) Stock Slides as Market Rises: Facts to Know Before You Trade

AbbVie (ABBV) closed the most recent trading day at $180.57, moving -0.27% from the previous trading session.
In Article Trend: Somewhat-Bullish
March 7, 2024 (15:17) / "Benzinga" (by Globe Newswire)

Anima Biotech to Present at RNA Leaders Europe Congress

BERNARDSVILLE, N.J., March 07, 2024 ( GLOBE NEWSWIRE ) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, today announced their participation in the upcoming RNA Leaders Europe Congress taking place on March 13th - 14th, 2024 in Basel, Switzerland.
In Article Trend: Neutral
March 5, 2024 (12:05) / "PR Newswire" (by REGENXBIO Inc.)

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL

ROCKVILLE, Md., March 5, 2024 /PRNewswire/ -- REGENXBIO Inc. ( Nasdaq: RGNX ) today reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy ( Duchenne ) ages 4 to11 years old, including RGX-202 ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (12:00) / "Canada Newswire" (by Inc.)

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial ... Canada ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)

Should First Trust Morningstar Dividend Leaders ETF ( FDL ) Be on Your Investing Radar?

Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
March 4, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
March 2, 2024 (11:30) / "Forbes" (by John Dobosz)

Berkshire Hathaway Has $168 Billion In Cash: These Stocks Should Be On Buffett's Buy List

Based on what Warren Buffett says and what he owns, it would not be surprising to see Berkshire buy stakes in these 13 stocks.
In Article Trend: Somewhat-Bullish
March 1, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) Beats Stock Market Upswing: What Investors Need to Know

In the most recent trading session, AbbVie (ABBV) closed at $178.91, indicating a +1.62% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
March 1, 2024 (21:04) / "GlobeNewswire" (by NurExone Biologic Inc)

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

TORONTO and HAIFA, Israel, March 01, 2024 ( GLOBE NEWSWIRE ) -- NurExone Biologic Inc. ( TSXV: NRX ) ( Germany: J90 ) ( the "Company" or "NurExone" ) , a pioneering biopharmaceutical company, is pleased to announce that Dr. Ina Sarel, the Head of CMC, Quality and Regulatory Affairs at NurExone, ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (21:04) / "Benzinga" (by Globe Newswire)

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

TORONTO and HAIFA, Israel, March 01, 2024 ( GLOBE NEWSWIRE ) -- NurExone Biologic Inc.
In Article Trend: Somewhat-Bullish
March 1, 2024 (19:26) / "Canada Newswire" (by JAMP Pharma)

JAMP Pharma Group announces the commercial launch and product availability for PrJamteki™, the first biosimilar of Stelara® ( ustekinumab ) in Canada

JAMP Pharma Group announces the commercial launch and product availability for PrJamteki™, the first biosimilar of ... Canada ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (15:48) / "Forbes" (by Jessica Burgoyne)

Allergan Lawsuit ( March Update )

Cosmetic surgery can help people feel more confident and comfortable with themselves. Unfortunately, some types of cosmetic surgery have historically increased the risk of life-threatening illnesses.
In Article Trend: Neutral
March 1, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie Inc. ( ABBV ) is Attracting Investor Attention: Here is What You Should Know

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
February 29, 2024 (22:22) / "Zacks Commentary" (by Shaun Pruitt)

C3.ai's ( AI ) Stock Is Soaring After Earnings But is it Time to Buy?

As one of the more promising artificial intelligence companies, let's see if it's time to buy C3.ai's (AI) stock after revenue and contract growth fuel its post-earnings rally.
In Article Trend: Somewhat-Bullish
February 29, 2024 (14:45) / "Motley Fool" (by George Budwell)

Better Dividend Growth Stock: AbbVie or Amgen?

A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy.
In Article Trend: Bullish
February 29, 2024 (13:50) / "Zacks Commentary" (by Kinjel Shah)

Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK

The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively ...
In Article Trend: Somewhat-Bullish
February 29, 2024 (13:00) / "Motley Fool" (by Prosper Junior Bakiny)

Is AbbVie Stock a Buy Now?

Some would say the growth story is over, but that view might be a bit myopic.
In Article Trend: Somewhat-Bullish
February 29, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)

Is iShares Core High Dividend ETF ( HDV ) a Strong ETF Right Now?

Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
February 29, 2024 (06:00) / "GlobeNewswire" (by argenx SE)

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

$374 million in fourth quarter and $1.2 billion in full year global net product sales ...
In Article Trend: Somewhat-Bullish
February 29, 2024 (06:00) / "Benzinga" (by Globe Newswire)

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update - argenx ( NASDAQ:ARGX )

$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024 On track to report data from six Phase 2 proof-of-concept trials by end of 2024
In Article Trend: Somewhat-Bullish
February 29, 2024 (05:45) / "Motley Fool" (by Motley Fool Transcribing)

C3.ai ( AI ) Q3 2024 Earnings Call Transcript

AI earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
February 28, 2024 (21:15) / "GlobeNewswire" (by Royalty Pharma plc)

Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference

NEW YORK, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at TD Cowen's 44th Annual Health Care Conference on March 5, 2024 at 10:30 a.m. ET.
In Article Trend: Somewhat-Bullish
February 28, 2024 (16:00) / "Benzinga" (by Benzinga Insights)

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie ( NYSE:ABBV )

AbbVie ABBV has outperformed the market over the past 10 years by 2.73% on an annualized basis producing an average annual return of 13.17%. Currently, AbbVie has a market capitalization of $313.90 billion.
In Article Trend: Somewhat-Bullish
February 28, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)

Should First Trust Value Line Dividend ETF ( FVD ) Be on Your Investing Radar?

Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (10:44) / "Motley Fool" (by Justin Pope)

Nearing Retirement? These Stocks Are as Cautious as They Come

Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further.
In Article Trend: Somewhat-Bullish
February 27, 2024 (16:30) / "Benzinga" (by Globe Newswire)

Vasomotor Menopausal Symptoms ( VMS ) Treatment Market Analysis 2024-2028: Projected Market Size And Major Growth Factors As Per The Business Research Company's Vasomotor Menopausal Symptoms ( VMS ) Treatment Global Market Report 2024

LONDON, Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Vasomotor Menopausal Symptoms ( VMS ) Treatment Global Market Report 2024, the vasomotor menopausal symptoms ( VMS ) treatment market has witnessed substantial growth, driven by a myriad of factors including ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (13:04) / "PR Newswire"

2024 SaaS Management Index Reveals an Average of $18M in Annual License Waste, with Significant Security Risks ... - PR Newswire

2024 SaaS Management Index Reveals an Average of $18M in Annual License Waste, with Significant Security Risks ... PR ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (10:45) / "Motley Fool" (by Cory Renauer)

3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade

These stocks don't offer the highest yields, but their payouts are growing fast.
In Article Trend: Bullish
February 26, 2024 (15:05) / "Benzinga" (by Globe Newswire)

Global L-Carnitine Market Size is Estimated to Reach USD 267.60 million by 2030, Growing at a CAGR of 4.7%: Straits Research

New York, United States, Feb. 26, 2024 ( GLOBE NEWSWIRE ) -- L-carnitine is an amino acid that aids in fat metabolism and is used as a supplement in patients with low energy levels. Red meat, salmon, peanut butter, dairy, and dairy products naturally contain L-carnitine.
In Article Trend: Somewhat-Bullish
February 26, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
February 26, 2024 (13:48) / "Benzinga" (by Vandana Singh)

Why Is Teva Pharma Stock Trading Higher Today? - Teva Pharmaceutical Indus ( NYSE:TEVA )

Friday, Alvotech ALVO and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd TEVA, announced the FDA approved Simlandi ( adalimumab-ryvk ) injection, as an interchangeable biosimilar to AbbVie Inc's ABBV Humira.
In Article Trend: Somewhat-Bullish
February 26, 2024 (08:24) / "PR Newswire"

Cosmetic Surgery and Procedure Devices Market size is set to grow by USD 6.73 billion from 2022 to 2027, Rest of the ... - PR Newswire

Cosmetic Surgery and Procedure Devices Market size is set to grow by USD 6.73 billion from 2022 to 2027, Rest of the ... PR ...
In Article Trend: Somewhat-Bullish
February 24, 2024 (12:04) / "Motley Fool" (by Keith Speights)

3 Dividend Stocks That Are No-Brainer Buys Right Now

These stocks check off multiple boxes for investors.
In Article Trend: Somewhat-Bullish
February 24, 2024 (01:15) / "GlobeNewswire" (by Alvotech)

Alvotech and Teva Announce U.S. Approval of SIMLANDI® ( adalimumab-ryvk ) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved ...
In Article Trend: Neutral
February 24, 2024 (01:15) / "GlobeNewswire" (by Alvotech)

Alvotech and Teva Announce U.S. Approval of SIMLANDI® ( adalimumab-ryvk ) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SIMLANDI ( adalimumab-ryvk ) injection, as an interchangeable biosimilar to Humira, ...
In Article Trend: Neutral
February 24, 2024 (00:26) / "Barrons" (by Randall W. Forsyth)

Super Micro Computer Can Raise Money for Free. It's Bad News for Interest Rates.

Why does the Federal Reserve need to lower interest rates when the capital markets are providing free money? That is, for tech winners such as Super Micro Computer , which was able to raise funds via a private convertible note deal this past week for $1.5 billion.
In Article Trend: Somewhat-Bullish
February 23, 2024 (13:37) / "Zacks Commentary" (by Kinjel Shah)

Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More

European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.
In Article Trend: Somewhat-Bullish
February 22, 2024 (13:05) / "PR Newswire" (by AbbVie)

AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... PR ...
In Article Trend: Somewhat-Bullish
February 22, 2024 (12:21) / "Zacks Commentary" (by Zacks Equity Research)

5 Top No-Load Mutual Funds to Enhance Your Returns

Invest in no-load mutual funds like FIKAX, FSPCX, VSMIX, STSEX and BMIIX to ensure high returns.
In Article Trend: Neutral
February 22, 2024 (10:15) / "Motley Fool" (by Justin Pope)

Is AbbVie Stock a Buy Now?

Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable.
In Article Trend: Somewhat-Bullish
February 21, 2024 (18:28) / "Decrypt.co" (by Andrew Throuvalas)

SEC Crypto Unit Leader Resigns After Spearheading Coinbase Lawsuit

Ladan Stewart once led federal lawsuits against Ripple and Coinbase, but may now turn crypto advocate in the private sector.
In Article Trend: Neutral
February 21, 2024 (16:45) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
In Article Trend: Bullish
February 21, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) Announces Appointment of New CEO Robert Michael

Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.
In Article Trend: Somewhat-Bullish
February 21, 2024 (13:00) / "PR Newswire" (by AbbVie)

BOTOX® Cosmetic ( onabotulinumtoxinA ) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
In Article Trend: Bullish
February 20, 2024 (16:30) / "Benzinga" (by Globe Newswire)

Congenital Diaphragmatic Hernia Drugs Market Size is Expected to Reach $5.8 Billion By 2028 At A CAGR Of More Than 7% As Per The Business Research Company's Congenital Diaphragmatic Hernia Drugs Global Market Report 2024

LONDON, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Congenital Diaphragmatic Hernia Drugs Global Market Report 2024, the global congenital diaphragmatic hernia ( CDH ) drugs market has experienced robust expansion in recent years, driven by various factors ...
In Article Trend: Bullish
February 20, 2024 (15:49) / "Zacks Commentary" (by Zacks Equity Research)

BeiGene ( BGNE ) to Report Q4 Earnings: What's in the Cards?

BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.
In Article Trend: Somewhat-Bullish
February 20, 2024 (15:46) / "MarketWatch" (by Eleanor Laise)

AbbVie taps new CEO as it faces fresh competition for blockbuster drug Humira

AbbVie's founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday.
In Article Trend: Somewhat-Bullish
February 20, 2024 (15:06) / "CNBC" (by Annika Kim Constantino)

AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez

Michael, who is AbbVie's chief operating officer, will become the company's second-ever CEO since the company spun out from Abbott Laboratories in 2013.
In Article Trend: Somewhat-Bullish
February 20, 2024 (13:30) / "GlobeNewswire" (by Disc Medicine Inc)

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

WATERTOWN, Mass., Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that ...
In Article Trend: Neutral
February 20, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)

Is Invesco Pharmaceuticals ETF ( PJP ) a Strong ETF Right Now?

Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
February 19, 2024 (15:15) / "Motley Fool" (by Keith Speights)

3 Magnificent Growth Stocks to Buy Right Now

These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.
In Article Trend: Somewhat-Bullish
February 19, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
February 19, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie Inc. ( ABBV ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
February 19, 2024 (04:52) / "Benzinga" (by Benzinga Neuro)

Oregon Rethinks Groundbreaking Drug Decriminalization Amid Escalating Opioid Crisis

In the wake of the escalating opioid crisis, the state of Oregon is reconsidering its groundbreaking drug decriminalization legislation. This move comes as the state grapples with a surge in drug-related fatalities and a lack of effective implementation of the existing law.
In Article Trend: Neutral
February 17, 2024 (09:59) / "Motley Fool" (by Justin Pope)

5 Vanguard ETFs That Could Help You Retire a Millionaire

Vanguard is one of the most trusted names on Wall Street.
In Article Trend: Somewhat-Bullish
February 16, 2024 (15:48) / "Investors Business Daily" (by Investor's Business Daily)

What The Future Holds For Google's 'Other Bets'

Other Bets And X Moonshots Key Google Stock's Future Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
February 16, 2024 (14:36) / "Zacks Commentary" (by Zacks Equity Research)

Ironwood ( IRWD ) Q4 Earnings Miss, Revenues Beat Marginally

Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
In Article Trend: Neutral
February 16, 2024 (10:50) / "Motley Fool" (by Keith Speights)

Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months

Analysts are quite bullish about these beaten-down stocks.
In Article Trend: Somewhat-Bullish
February 15, 2024 (16:30) / "Benzinga" (by Globe Newswire)

Myelodysplastic Syndrome ( MDS ) Drugs Global Market Report 2024: Strong Growth Projected with Increasing Incidences of Myeloid Leukemia As Per The Business Research Company's Myelodysplastic Syndrome ( MDS ) Drugs Global Market Report 2024

LONDON, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Myelodysplastic Syndrome ( MDS ) Drugs Global Market Report 2024, the myelodysplastic syndrome ( MDS ) drugs market size has exhibited robust growth in recent years, with the market poised to reach $3.47 billion ...
In Article Trend: Somewhat-Bullish
February 15, 2024 (14:00) / "PR Newswire" (by Inc.)

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with ... PR ...
In Article Trend: Somewhat-Bullish
February 15, 2024 (14:00) / "Canada Newswire" (by Dragonfly Therapeutics)

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with ... Canada ...
In Article Trend: Somewhat-Bullish
February 15, 2024 (13:00) / "PR Newswire"

CollPlant Issues Letter to Shareholders - PR Newswire

CollPlant Issues Letter to Shareholders PR ...
In Article Trend: Somewhat-Bullish
February 15, 2024 (12:45) / "Motley Fool" (by Prosper Junior Bakiny)

2 Magnificent Growth Stocks to Buy With $500

No need to break the bank to invest in promising stocks.
In Article Trend: Somewhat-Bullish
February 14, 2024 (19:02) / "Investors Business Daily" (by GLENN LARKIN)

AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating

When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is AbbVie ( ABBV ) , which had its Relative Strength ( RS ) Rating upgraded from 80 to 84 Wednesday.
In Article Trend: Bullish
February 14, 2024 (16:02) / "GlobeNewswire" (by Genmab A/S)

Genmab Publishes 2023 Annual Report

Company Announcement ...
In Article Trend: Neutral
February 14, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)

AbbVie Clears Key Benchmark, Hitting 80-Plus RS Rating

When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is AbbVie ( ABBV ) , which had its Relative Strength ( RS ) Rating upgraded from 80 to 84 Wednesday.
In Article Trend: Bullish
February 13, 2024 (15:55) / "Benzinga" (by Globe Newswire)

Global Inhalation Anaesthesia Market Size is Projected to Reach USD 1.84 billion by 2031, Growing at a CAGR of 4.2%: Straits Research

New York, United States, Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- Inhalation Anaesthesia is a common method in medical procedures to achieve general anesthesia.
In Article Trend: Somewhat-Bullish
February 13, 2024 (11:00) / "Zacks Commentary" (by Zacks Investment Research)

The Zacks Analyst Blog Highlights AbbVie, Applied Materials, American Express, Centene and Aspen

AbbVie, Applied Materials, American Express, Centene and Aspen are included in this Analyst Blog.
In Article Trend: Neutral
February 12, 2024 (20:53) / "Zacks Commentary" (by Sheraz Mian)

Top Stock Reports for AbbVie, Applied Materials & American Express

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Applied Materials, Inc. (AMAT) and American Express Company (AXP).
In Article Trend: Somewhat-Bullish
February 12, 2024 (18:00) / "Stocknews.com" (by StockNews.com Staff)

ABBV: Unleash Gain Potential With 3 Pharma Stocks to Consider

The rise in chronic diseases, advancements in technology, and a strong research and development pipeline have ignited a heightened demand for pharmaceutical products and services. Moreover, the pharmaceutical sector's resilience to economic fluctuations offers a stable environment for companies ...
In Article Trend: Somewhat-Bullish
February 12, 2024 (17:49) / "Stocknews.com" (by StockNews.com Staff)

ZTS: Zoetis ( ZTS ) : Analyzing Earnings for Potential Gains

Zoetis Inc. ( ZTS ) is a leading force in the realm of animal health, specializing in the discovery, development, manufacturing, and global distribution of vital medicines, vaccines, and diagnostic tools.
In Article Trend: Somewhat-Bullish
February 12, 2024 (15:00) / "Money Morning"

Three Stocks: AbbVie, Viking Therapeutics, and Cloudflare

Just like we spoke about in early December, AbbVie ( ABBV ) is starting to feel an acquisition spree it was on last year. And just as we said, long-dated put options back then would've yielded well now that the company lowered its guidance this morning due to the "dilutive impact" of its ...
In Article Trend: Somewhat-Bullish
February 12, 2024 (14:16) / "Zacks Commentary" (by Zacks Equity Research)

Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY

Let's take a look at three biotech/drug companies, BIIB, ZTS, and INCY, slated to release quarterly results on Feb 13.
In Article Trend: Somewhat-Bullish
February 12, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)

3 Top Dividend Stocks to Maximize Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
February 12, 2024 (12:51) / "MarketWatch" (by Ciara Linnane)

AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen

AbbVie Inc.'s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen.
In Article Trend: Neutral
February 12, 2024 (12:30) / "Motley Fool" (by Rachel Warren)

Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?

These incredible businesses have long histories of successes behind them, and more to come.
In Article Trend: Somewhat-Bullish
February 12, 2024 (11:45) / "Benzinga" (by Globe Newswire)

Global Generic Drugs Market Size is Estimated to Reach USD 546.03 Billion by 2031, Growing at a CAGR of 4.1%: Straits Research

New York, United States, Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Generic medications are bioequivalent to name-brand medications, meaning they have the same active components and therapeutic results. Similarities exist in the dosages, risks, consequences, side effects, strengths, intended purposes, ...
In Article Trend: Neutral
February 11, 2024 (13:25) / "Motley Fool" (by Prosper Junior Bakiny)

These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy

The drugmaker is handling its biggest obstacle yet relatively well.
In Article Trend: Somewhat-Bullish
February 9, 2024 (13:33) / "Benzinga" (by Avi Kapoor)

Jim Cramer Looks At Blackstone, Praises MercadoLibre: 'They're Incredibly Smart' - Blackstone ( NYSE:BX ) , AbbVie ( NYSE:ABBV )

On CNBC's "Mad Money Lightning Round," Jim Cramer said Freeport-McMoRan Inc. FCX could go higher by a "couple of points, once the Chinese start manipulating their market higher, but that's all you're going to get from them. We have to go higher quality." Freeport-McMoRan confirmed that Kathleen L.
In Article Trend: Somewhat-Bullish
February 8, 2024 (21:15) / "Investing News Network" (by Meagen Seatter)

Pharma Stocks: 5 Biggest Companies in 2024

Companies in this sector are constantly researching and creating innovative treatments for various medical conditions, including immuno-oncology, neurology and rare diseases. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.
In Article Trend: Neutral
February 8, 2024 (20:17) / "Benzinga" (by Globe Newswire)

Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights

Exton, Pennsylvania, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- As Age-Related Macular Degeneration ( AMD ) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD, the need for optimal treatment solutions becomes increasingly evident.
In Article Trend: Somewhat-Bullish
February 8, 2024 (13:00) / "Canada Newswire" (by AbbVie Canada)

AbbVie's VYALEV™ ( foslevodopa/foscarbidopa solution ) Available for the Treatment of Advanced Parkinson's Disease in Canada

AbbVie's VYALEV™ ( foslevodopa/foscarbidopa solution ) Available for the Treatment of Advanced Parkinson's Disease ... Canada ...
In Article Trend: Somewhat-Bullish
February 8, 2024 (06:00) / "PR Newswire"

Intrauterine Contraceptive Devices (IUD) Market to grow by USD 965.49 million at a CAGR of 3.98% from 2022 to 2027 ... - PR Newswire

Intrauterine Contraceptive Devices ( IUD ) Market to grow by USD 965.49 million at a CAGR of 3.98% from 2022 to 2027 ... PR ...
In Article Trend: Somewhat-Bullish
February 7, 2024 (17:30) / "Benzinga" (by Benzinga Insights)

AbbVie Options Trading: A Deep Dive into Market Sentiment - AbbVie ( NYSE:ABBV )

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 12 unusual trades. Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
February 7, 2024 (15:17) / "Benzinga" (by Globe Newswire)

Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis

BERNARDSVILLE, N.J., Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate.
In Article Trend: Somewhat-Bullish
February 6, 2024 (19:19) / "Benzinga" (by Vandana Singh)

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst - Axsome Therapeutics ( NASDAQ:AXSM )

UBS initiated coverage on Axsome Therapeutics Inc AXSM, a biotech firm focused on developing and marketing therapies for central nervous disorders. UBS analyst is bullish on Axsom's depression drug Auvelity's launch and pipeline opportunities with upcoming late-stage clinical read-outs.
In Article Trend: Somewhat-Bullish
February 6, 2024 (16:16) / "Zacks Commentary" (by Zacks Equity Research)

Novartis ( NVS ) to Buy MorphoSys & Add Late-Stage Oncology Drug

Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.
In Article Trend: Somewhat-Bullish
February 6, 2024 (16:00) / "Benzinga" (by Benzinga Insights)

$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today - AbbVie ( NYSE:ABBV )

AbbVie ABBV has outperformed the market over the past 10 years by 2.73% on an annualized basis producing an average annual return of 13.2%. Currently, AbbVie has a market capitalization of $303.65 billion.
In Article Trend: Somewhat-Bullish
February 6, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie Inc. ( ABBV ) is Attracting Investor Attention: Here is What You Should Know

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
February 6, 2024 (14:00) / "Motley Fool" (by George Budwell)

2 Magnificent Dividend Growth Stocks to Load Up On Right Now

These two dividend-growth stocks are fantastic buys.
In Article Trend: Bullish
February 6, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)

Is WisdomTree U.S. High Dividend ETF ( DHS ) a Strong ETF Right Now?

Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
February 5, 2024 (23:55) / "Motley Fool" (by Eric Volkman)

Why AbbVie Stock Flew Higher on Monday

Investors and pundits alike continued to be impressed by the company's latest earnings report.
In Article Trend: Somewhat-Bullish
February 5, 2024 (21:20) / "Investors Business Daily" (by ALLISON GATLIN)

Vertex Scores Big With Its Next-Gen Cystic Fibrosis Drug

VRTX Stock Rises On Quarterly Beat As Next-Gen CF Drug Scores Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
February 5, 2024 (18:08) / "Investors Business Daily" (by Investor's Business Daily)

Why Amgen's Weight-Loss News Just Sent Lilly To A Record High

Amgen Stock Slumps As It Looks To Take On Weight-Loss Drugs Leaders Lilly, Novo Investor's Business Daily ...
In Article Trend: Neutral
February 5, 2024 (16:45) / "Zacks Commentary" (by Zacks Equity Research)

This is Why AbbVie ( ABBV ) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
In Article Trend: Bullish
February 5, 2024 (15:09) / "Zacks Commentary" (by Zacks Equity Research)

Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More

Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
In Article Trend: Neutral
February 5, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
February 5, 2024 (13:54) / "Motley Fool" (by Cory Renauer)

Better Dividend Stock: Pfizer vs. AbbVie

Both offer above-average yields but which can deliver the most dividend income over the long run?
In Article Trend: Somewhat-Bullish
February 5, 2024 (13:50) / "Benzinga" (by Avi Kapoor)

AbbVie Analysts Boost Their Forecasts Following Strong Earnings - AbbVie ( NYSE:ABBV )

AbbVie Inc ABBV reported better-than-expected fourth-quarter earnings on Friday. AbbVie reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77. Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the consensus of $14.02 billion, ...
In Article Trend: Somewhat-Bullish
February 5, 2024 (13:09) / "Benzinga" (by Avi Kapoor)

Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday - Apellis Pharmaceuticals ( NASDAQ:APLS ) , AbbVie ( NYSE:ABBV )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Raymond James cut the price target for Skechers U.S.A., Inc. SKX from $68 to $66.
In Article Trend: Somewhat-Bullish
February 5, 2024 (11:00) / "Zacks Commentary" (by Zacks Investment Research)

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, AbbVie and Novartis

Eli Lilly, Novo Nordisk, AbbVie and Novartis have been highlighted in this Industry Outlook article.
In Article Trend: Somewhat-Bullish
February 5, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)

Stocks To Watch: AbbVie Sees RS Rating Jump To 81

AbbVie ( ABBV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Monday, with an increase from 78 to 81. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
In Article Trend: Bullish
February 4, 2024 (10:50) / "Motley Fool" (by Keith Speights)

3 Fabulous Dividend Stocks to Buy in February

These stocks offer great dividends and more.
In Article Trend: Somewhat-Bullish
February 2, 2024 (20:45) / "Motley Fool" (by Motley Fool Transcribing)

AbbVie ( ABBV ) Q4 2023 Earnings Call Transcript

ABBV earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
February 2, 2024 (18:04) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) Q4 Earnings Beat, Raises Sales View for Key Drugs

AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
In Article Trend: Neutral
February 2, 2024 (17:15) / "Investors Business Daily" (by IBD STAFF)

Stocks Handle Huge Earnings, Fed, Jobs Report: Weekly Review

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
February 2, 2024 (16:12) / "Benzinga" (by Vandana Singh)

AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall - Cerevel Therapeutics Hldg ( NASDAQ:CERE ) , AbbVie ( NYSE:ABBV )

Friday, AbbVie Inc ABBV reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77. Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the consensus of $14.02 billion. The immunology portfolio generated $6.95 billion in sales, down 12.3%.
In Article Trend: Somewhat-Bullish
February 2, 2024 (15:45) / "Zacks Commentary" (by Zacks Equity Research)

Nonfarm Payrolls Increased More Than Expected

The big jobs numbers out this week came from this morning's U.S. Bureau of Labor Statistics' ( BLS ) Employment Situation report, which surprised to the upside in a major way: 353K new jobs created for January, nearly double the 180K or so analysts were looking for.
In Article Trend: Neutral
February 2, 2024 (15:22) / "Zacks Commentary" (by Mark Vickery)

BLS Jobs Up Big: 353K, 3.7% Unemployment

353K new jobs created for January are nearly double the 180K or so analysts were looking for.
In Article Trend: Neutral
February 2, 2024 (14:08) / "Benzinga" (by Globe Newswire)

North America Cosmetic Surgery Market is Expected to Reach USD 29.2 billion, Advancing at a CAGR of 6.8% by 2031: Transparency Market Research, Inc.

Wilmington, Delaware, United States, Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The North America cosmetic surgery market is estimated to flourish at a CAGR of 6.8% from 2023 to 2031.
In Article Trend: Bullish
February 2, 2024 (13:56) / "Investors Business Daily" (by Investor's Business Daily)

AbbVie Expects Two Drugs To Top $27 Billion In Sales. And Neither Is Humira.

AbbVie Stock Rises On Long-Term Guidance, Calling For $27 Billion From Two Key Drugs Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
February 2, 2024 (13:47) / "Zacks Commentary" (by Kinjel Shah)

4 Large Drug Stocks Trying to Survive the Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.
In Article Trend: Somewhat-Bullish
February 2, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) Q4 Earnings and Revenues Top Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 1.09% and 1.78%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Somewhat-Bullish
February 2, 2024 (12:40) / "MarketWatch" (by Eleanor Laise)

AbbVie's fourth-quarter sales top estimates despite plunging Humira revenues

AbbVie on Friday reported fourth-quarter sales that topped analyst estimates, even as it faces low-cost competition for its top-seller Humira.
In Article Trend: Somewhat-Bullish
February 2, 2024 (12:24) / "Benzinga" (by Shanthi Rexaline)

Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )

Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. META, Amazon, Inc. AMZN, and Apple, Inc. AAPL. Earnings remain mixed, raising concerns about both the economy and corporate profit growth.
In Article Trend: Neutral
February 1, 2024 (21:44) / "Investors Business Daily" (by Investor's Business Daily)

Two Titans Signal Strong End To Huge Week Of Earnings

Dow Jones Futures: Meta, Amazon Fuel Techs Late, China Woes Hit Apple. Jobs Report Looms Investor's Business Daily ...
In Article Trend: Neutral
February 1, 2024 (12:45) / "Zacks Commentary" (by Zacks Equity Research)

Merck ( MRK ) Beats Q4 Earnings Estimates

Merck (MRK) delivered earnings and revenue surprises of 133.33% and 0.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
January 31, 2024 (18:31) / "Benzinga" (by Benzinga Insights)

This Is What Whales Are Betting On AbbVie - AbbVie ( NYSE:ABBV )

Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations and 80% ...
In Article Trend: Neutral
January 30, 2024 (21:15) / "GlobeNewswire" (by Royalty Pharma plc)

Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024

NEW YORK, Jan. 30, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open.
In Article Trend: Neutral
January 30, 2024 (19:07) / "PR Newswire" (by Piramal Pharma Ltd)

Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024

MUMBAI, India, Jan. 30, 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA | BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023. • Revenue from ...
In Article Trend: Somewhat-Bullish
January 30, 2024 (19:02) / "PR Newswire" (by Piramal Pharma Ltd)

Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024

MUMBAI, India, Jan. 30, 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA | BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023. • Revenue from ...
In Article Trend: Somewhat-Bullish
January 30, 2024 (19:02) / "Canada Newswire" (by Piramal Pharma Ltd)

Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024

MUMBAI, India, Jan. 30, 2024 /CNW/ -- Piramal Pharma Limited ( NSE: PPLPHARMA | BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023. • Revenue from ...
In Article Trend: Somewhat-Bullish
January 30, 2024 (19:02) / "Benzinga" (by PRNewswire)

Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024

MUMBAI, India, Jan. 30, 2024 /PRNewswire/ -- Piramal Pharma Limited PPLPHARMA, a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023.
In Article Trend: Somewhat-Bullish
January 30, 2024 (19:02) / "Benzinga" (by PRNewswire)

Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024

MUMBAI, India, Jan. 30, 2024 /CNW/ -- Piramal Pharma Limited PPLPHARMA, a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023.
In Article Trend: Somewhat-Bullish
January 30, 2024 (18:50) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) to Report Q4 Earnings: What's in the Cards?

AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.
In Article Trend: Somewhat-Bullish
January 30, 2024 (15:00) / "Zacks Commentary" (by Zacks Equity Research)

Eli Lilly ( LLY ) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
January 30, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)

Unveiling AbbVie ( ABBV ) Q4 Outlook: Wall Street Estimates for Key Metrics

Evaluate the expected performance of AbbVie (ABBV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
In Article Trend: Neutral
January 30, 2024 (14:00) / "Benzinga" (by Avi Kapoor)

Goldman Sachs, AbbVie And A Major Chipmaker: CNBC's 'Final Trades' - AbbVie ( NYSE:ABBV ) , Goldman Sachs Gr ( NYSE:GS )

On CNBC's "Halftime Report Final Trades," Steve Weiss of Short Hills Capital Partners said Taiwan Semiconductor Manufacturing Company Limited TSM goes higher. Taiwan Semiconductor Manufacturing is reportedly eyeing its second Japanese plant in the same town as its first in Kumamoto prefecture.
In Article Trend: Somewhat-Bullish
January 30, 2024 (13:15) / "Benzinga" (by Globe Newswire)

Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU

Treatment with JNT-517 demonstrated a statistically significant mean blood phenylalanine reduction of 51% versus baseline Jnana has adapted the ongoing trial to accelerate the program and aims to advance JNT-517 directly into a pivotal study in early 2025
In Article Trend: Somewhat-Bullish
January 29, 2024 (23:08) / "Zacks Commentary" (by Derek Lewis)

3 Stocks Enjoying Favorable Analyst Coverage

All three of these stocks have seen upgrades from analysts in recent days. Is it time to buy?
In Article Trend: Bullish
January 29, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)

AbbVie ( ABBV ) Stock Sinks As Market Gains: Here's Why

The latest trading day saw AbbVie (ABBV) settling at $163.91, representing a -0.3% change from its previous close.
In Article Trend: Somewhat-Bullish
January 29, 2024 (19:04) / "Benzinga" (by Vandana Singh)

AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures - Cerevel Therapeutics Hldg ( NASDAQ:CERE ) , AbbVie ( NYSE:ABBV )

William Blair has upgraded AbbVie Inc ABBV, noting confidence in the company's growth outlook over the near and long term as it heads into 2024.
In Article Trend: Bullish



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.